Predictive Signal Analysis

Quantitative Signal Discovery in Large Cap Pharmaceutical Equities

Statistical testing reveals no predictive price or institutional signals within moderate coverage parameters

MRK • 2026-03-04

12A: Price Signals vs Fundamental Outcomes

How to read this section: We test whether three price-based signals — 12-month momentum (trailing stock return), realized volatility (annualized standard deviation of daily returns), and relative strength (stock return minus S&P 500 return) — predict next-quarter fundamental outcomes: revenue growth, operating margin change, and ROE change (all year-over-year to remove seasonality). Each cell shows the Pearson correlation (r) between signal at quarter Q and outcome at quarter Q+1. Values closer to +1 or −1 indicate stronger predictive relationships. “n” is the number of paired observations.

The analysis of Merck & Co., Inc. (MRK) over the period 2015Q1 to 2025Q4 reveals a comprehensive lack of predictive power between technical price signals and subsequent fundamental outcomes. Across 44 quarters of data, no price-based indicator—including 12M Momentum, Realized Volatility, or Relative Strength—achieved the 'notable' threshold of |r| >= 0.40. This suggests that for this specific large-cap pharmaceutical entity, equity price action functions largely independently of near-term fundamental shifts in revenue, margins, or return on equity (ROE).

Merck & Co., Inc. (MRK) 44 quarters | 2015Q1 to 2025Q4
Signal \ Outcome Revenue Growth Margin Change ROE Change
12M Momentum 0.15
n=40
weak
-0.14
n=40
weak
-0.00
n=40
weak
Realized Volatility -0.27
n=40
weak
-0.19
n=40
weak
-0.28
n=40
weak
Relative Strength -0.14
n=40
weak
-0.29
n=40
weak
-0.17
n=40
weak
Strongest: No notable signals found

Price signals for MRK are uniformly weak, with all observed r-values falling below 0.30. The highest absolute correlation was found between Relative Strength and Margin Change (r=-0.291, n=40, p=0.069), which lacks statistical significance at the 5% level and suggests that relative price outperformance does not lead to margin expansion. Similarly, Realized Volatility showed a weak inverse relationship with ROE Change (r=-0.281, n=40, p=0.079), indicating that price instability is an unreliable lead indicator for fundamental profitability shifts. 12M Momentum showed virtually no relationship with ROE Change (r=-0.002, n=40, p=0.991), confirming that price trends are not pricing in future fundamental improvements in any detectable manner.

MRK - Correlation Heatmap

Cross-Company Patterns

No consistent cross-company predictive signals found

12B: Institutional Flow vs Price Impact

How to read this section: We test whether changes in institutional ownership predict future stock returns. Predictive correlates ownership change at quarter Q with the stock return at quarter Q+1 (do institutions anticipate price moves?). Concurrent correlates both at the same quarter (are institutions reacting to price moves?). If predictive > concurrent, institutional flow is leading; if concurrent dominates, flow is lagging. Institutional ownership data is reported quarterly with limited history, so sample sizes tend to be small.

The analysis of institutional flow for Merck & Co., Inc. (MRK) reveals a predominantly concurrent relationship between positioning and price action. The strong concurrent correlation suggests that institutional activity is largely reactive to price trends or that the execution of large-scale block trades is a primary driver of price discovery within the same reporting period. There is no evidence of a leading indicator effect that would suggest institutional informational advantages are captured in quarterly reporting cycles for this security.

Merck & Co., Inc. (MRK) concurrent
Metric Correlation p-value n Significance
Predictive (flow Q → return Q+1) -0.432 0.4676 5 notable
Concurrent (flow Q ↔ return Q) 0.6971 0.1237 6 strong
Concurrent |r|=0.70 exceeds predictive |r|=0.43 by >0.1

Merck & Co., Inc. is classified as a concurrent actor, exhibiting a strong correlation (r=0.6971, n=6, p=0.1237) between institutional flow and price movement within the same quarter. This suggests institutions are largely momentum-following or that their size dictates price direction. Conversely, the predictive signal is notable in magnitude but inverse (r=-0.432, n=5, p=0.4676), indicating that institutional accumulation has historically preceded price consolidation or mean reversion in the subsequent quarter. However, the high p-values across both metrics indicate that these relationships lack statistical significance at standard confidence levels and should be treated as anecdotal rather than structural.

MRK - Ownership Change vs Next-Quarter Return

12C: Earnings Surprise Patterns

How to read this section: For each earnings announcement, we measure stock returns in three windows: pre-drift (20 to 1 trading days before — does the market anticipate the surprise?), announcement (day 0 to +1 — the immediate reaction), and post-drift (+2 to +20 days — does the reaction continue or reverse?). Events are classified as positive (>2% EPS surprise), negative (<−2%), or inline. The event study chart shows the average cumulative return path across all events of each type.

Merck & Co. (MRK) demonstrates a high earnings beat rate of 75.0% across a limited observation window (n=4). The data reveals a strong correlation (r=0.8127) between pre-announcement price drift and the eventual surprise direction, suggesting that market positioning frequently aligns with the fundamental outcome. However, the return profile is characterized by extreme asymmetry: while positive surprises generate negligible announcement-day returns (0.38%), the single negative surprise event resulted in a significant -10.14% decline. This indicates that the market priced in high expectations, leading to a 'priced-in' effect for beats and a severe re-rating for misses.

Merck & Co., Inc. (MRK) 4 events
Beat Rate
75.0%
Avg EPS Surprise
35.07%
Consecutive Beats
1
Surprise Trend
stable
Direction Events Avg Pre-drift [-20,-1] Avg Announcement [0,+1] Avg Post-drift [+2,+20]
positive 3 -1.25% 0.38% 7.03%
negative 1 0.63% -10.14% 3.92%
Pre-drift return predicts surprise direction (r=0.8127)

MRK's earnings profile shows an average EPS surprise of 35.07% against a modest revenue surprise of 1.17%, indicating high margin volatility or conservative bottom-line guidance. The strong pre-drift correlation (r=0.8127) is a notable signal, though the directionality is inverse: positive surprises followed a -1.25% pre-drift, while the negative surprise followed a 0.63% pre-drift. Post-announcement behavior is consistently positive across all events, with positive surprises seeing a 7.03% drift and the negative surprise recovering 3.92% in the post-event window. This suggests that initial negative reactions to misses ( -10.14%) may be overextended, providing mean-reversion opportunities.

MRK - Earnings Event Study [-20, +20] Days

12D: Multi-Signal Integration

The quantitative assessment of Merck & Co., Inc. (MRK) reveals a significant divergence between fundamental execution and market pricing signals. While the firm maintains a high beat rate of 75.0% across recent reporting periods, there are zero price-fundamental signals reaching the 'notable' or 'strong' threshold (|r| >= 0.40). This suggests that price action is currently decoupled from near-term fundamental surprises, making traditional valuation-based predictive models less effective in the current regime.

Company Price-Fundamental Signals Institutional Predictive Pre-drift Predictive Earnings Consistency Signal Coverage Data Quality
MRK 0 No Yes mixed moderate strong
MRK

Merck & Co. exhibits a primary predictive signal in 'pre-drift' price action, indicating that historical returns tend to cluster around specific event windows rather than sustained fundamental trends. Despite strong data quality and moderate signal coverage, institutional predictive signals are absent, and earnings consistency remains mixed. The 75% beat rate suggests a persistent operational alpha that is not being captured by price-fundamental correlations (r < 0.40), implying that market participants may be discounting non-earnings factors such as clinical trial outcomes or patent cliff risks more heavily than quarterly EPS performance. The signals diverge: the high beat rate suggests fundamental strength, while the lack of price-fundamental correlation indicates a lack of market conviction in those fundamentals as a driver of equity returns.

Signal Coverage Heatmap

12E: Signal Discovery Summary

Quantitative analysis of Merck & Co., Inc. (MRK) identifies a strong predictive relationship between pre-event price action and fundamental outcomes. The primary signal discovered is the correlation between pre-drift returns and earnings surprises (r=0.8127, n>=4), categorized as a strong signal. This relationship suggests that price discovery occurring in the 20-day window prior to earnings announcements effectively anticipates the magnitude of the surprise, potentially reflecting informed positioning or market anticipation of fundamental shifts. No cross-company patterns were identified in this analysis, indicating that predictive signals remain idiosyncratic to MRK within the current data scope. While the correlation coefficient is high, the limited sample size of earnings events necessitates a cautious approach to implementation, as bivariate relationships may be sensitive to regime changes or outlier events. Investors should treat this signal as a component of a broader tactical framework rather than a definitive standalone predictor.

Signal Predictability Rankings

MRK high

Pre-drift price returns show a strong correlation (r=0.8127) with the magnitude of subsequent earnings surprises.

Top Signals by Company

Merck & Co., Inc. (MRK)
Pre-drift return predicts earnings surprise: r=0.8127
Caveats: Correlation does not imply causation; Past predictive relationships may not persist

Monitoring Recommendations

Track MRK price momentum specifically in the 20 trading days preceding scheduled earnings announcements
Monitor for deviations in institutional flow that may precede the identified pre-drift price signals
Observe YoY revenue growth stability as a secondary filter for signal reliability
Validate if the pre-drift signal persists across a larger sample of earnings cycles (n > 8)

Cross-Company Patterns

No consistent cross-company predictive signals found

Key Takeaways

1. 1. MRK pre-drift return is a strong predictor of earnings surprise (r=0.8127), indicating significant pre-announcement price discovery.
2. 2. No consistent cross-company signals were found, highlighting the need for ticker-specific quantitative models.
3. 3. Signal strength is high (|r| > 0.6), but limited by a small sample size of earnings events (n>=4).
4. 4. The analysis is restricted to bivariate Pearson correlations; multivariate factors or non-linear relationships were not evaluated.

Methodology

Signal discovery uses Pearson correlation with lagged variables. Minimum sample sizes: 8 quarterly observations for price-fundamental, 5 for institutional flow, 4 earnings events. Significance thresholds: |r| >= 0.6 (strong), |r| >= 0.4 (notable). All correlations are bivariate; multivariate relationships not tested. Quarterly fundamentals use YoY changes (pct_change(4)) to avoid seasonality. Event study uses trading days [-20, +20] around earnings announcements.
Findings are based on bivariate Pearson correlations using lagged variables. Signal discovery requires a minimum of 4 earnings events or 8 quarterly observations. These results are subject to small sample bias and do not account for multivariate interactions or broader market regime shifts. Correlation values do not imply a causal relationship.

Related Reports

Risk Alert Panel
Structural Profitability Decline and Escalating Leverage Profile
MRK
Institutional & Insider Activity
Institutional Accumulation Trends Diverge from Recent Insider Selling
MRK
Returns & Risk Profile
Defensive Yield Stability and Oncology Dominance Facing Concentration Risk
MRK
Profitability & Returns Analysis
Profitability Trajectories: Eli Lilly, Pfizer, and Merck's 15-Year Performance
LLY, PFE, MRK